# Study Of Sunitinib With Capecitabine In Breast Cancer

> **NCT00662025** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 63 (actual)

## Conditions studied

- Advanced/Metastatic Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00662025
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-12
- **Final completion:** 2012-05
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2013-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662025, "Study Of Sunitinib With Capecitabine In Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00662025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*